BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+27.77%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$8.73B
AUM Growth
+$8.73B
(+21%)
Cap. Flow
+$239M
Cap. Flow
% of AUM
2.73%
Top 10 Holdings %
Top 10 Hldgs %
31.85%
Holding
234
New
17
Increased
81
Reduced
66
Closed
12
Top Buys
| 1 |
Biogen
BIIB
|
$136M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$65.8M |
| 3 |
Mersana Therapeutics
MRSN
|
$51.3M |
| 4 |
Arvinas
ARVN
|
$46.7M |
| 5 |
AbbVie
ABBV
|
$36.3M |
Top Sells
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$154M |
| 2 |
Halozyme
HALO
|
$60.8M |
| 3 |
Pacific Biosciences
PACB
|
$57.2M |
| 4 |
CareDx
CDNA
|
$55.9M |
| 5 |
Charles River Laboratories
CRL
|
$52M |
Sector Composition
| 1 | Healthcare | 95.9% |
| 2 | Technology | 0.6% |
| 3 | Industrials | 0.33% |
| 4 | Financials | 0.11% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Q32 Bio
QTTB
$20.9M
| $19.6M | 0.22% |
1,737,122
| – | – |
|
102
Voyager Therapeutics
VYGR
$204M
| $19.4M | 0.22% |
2,712,083
| – | – |
|
103
Illumina
ILMN
$15.2B
| $19.4M | 0.22% |
52,366
-6,181
| -11% | -$2.29M |
|
|
ACCD
104
DELISTED
Accolade, Inc. Common Stock
ACCD
| $16.8M | 0.19% |
385,308
+175,981
| +84% | +$7.66M |
|
105
Cooper Companies
COO
$13.3B
| $15.8M | 0.18% |
43,510
+18,165
| +72% | +$6.6M |
|
106
Avantor
AVTR
$8.74B
| $14.4M | 0.17% |
512,216
+205,127
| +67% | +$5.77M |
|
|
CELL
107
DELISTED
PhenomeX Inc. Common Stock
CELL
| $14.4M | 0.16% |
160,505
+52,995
| +49% | +$4.74M |
|
|
XENT
108
DELISTED
Intersect ENT, Inc
XENT
| $14.2M | 0.16% |
619,481
+146,099
| +31% | +$3.35M |
|
|
OXFD
109
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $14M | 0.16% |
800,157
| – | – |
|
110
Regeneron Pharmaceuticals
REGN
$59.8B
| $13.4M | 0.15% |
27,700
+7,700
| +39% | +$3.72M |
|
111
Transmedics
TMDX
$3.65B
| $12.8M | 0.15% |
641,612
+64,465
| +11% | +$1.28M |
|
112
Pulmonx
LUNG
$67.6M
| $12.2M | 0.14% |
+176,510
| New | +$12.2M |
|
113
Legend Biotech
LEGN
$6.64B
| $11.7M | 0.13% |
+416,341
| New | +$11.7M |
|
|
VCRA
114
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $11.1M | 0.13% |
268,171
+66,781
| +33% | +$2.77M |
|
115
Outset Medical
OM
$245M
| $10.8M | 0.12% |
189,711
+109,790
| +137% | +$6.24M |
|
|
IMAB
116
I-MAB
IMAB
$380M
| $9.58M | 0.11% |
203,212
+138,212
| +213% | +$6.52M |
|
|
TRHC
117
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $9.34M | 0.11% |
217,975
-26,494
| -11% | -$1.13M |
|
|
EAR
118
DELISTED
Eargo, Inc. Common Stock
EAR
| $8.81M | 0.1% |
+196,522
| New | +$8.81M |
|
119
Dentsply Sirona
XRAY
$2.77B
| $8.33M | 0.1% |
159,129
| – | – |
|
120
CVS Health
CVS
$93B
| $8.24M | 0.09% |
120,595
-66,386
| -36% | -$4.53M |
|
|
SGEN
121
DELISTED
Seagen Inc. Common Stock
SGEN
| $8.16M | 0.09% |
46,600
| – | – |
|
122
Inogen
INGN
$213M
| $8M | 0.09% |
179,143
+30,231
| +20% | +$1.35M |
|
123
Ultragenyx Pharmaceutical
RARE
$3.04B
| $5.68M | 0.07% |
41,000
| – | – |
|
124
Cidara Therapeutics
CDTX
$1.61B
| $5.65M | 0.06% |
2,822,495
| – | – |
|
125
Gilead Sciences
GILD
$140B
| $4.93M | 0.06% |
84,600
-39,100
| -32% | -$2.28M |
|